About Us

Meet Celsion

Celsion Corporation is a fully integrated biopharmaceutical company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies. Our lead product candidate is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in a phase 3 clinical trial for the treatment of primary liver cancer and a phase 2 clinical trial for the treatment of recurrent chest wall breast cancer. Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers.

We have 3 platform technologies providing the basis for the future development of a range of therapeutics for difficult-to-treat forms of cancers. With these technologies we are working to develop and commercialize more efficient, effective, and targeted oncology therapies that maximize efficacy while minimizing side effects common to cancer treatments.

Our mission

Our mission is to transform the landscape of cancer treatment with novel targeting technologies. Our ultimate goal is to find a cure for challenging cancers, transitioning from the passion of what is possible to the science of what is proven.

Our platform technologies

We currently have three platform technologies providing the basis for the future development of a range of therapeutics for difficult-to-treat forms of cancer.

Chemotherapy

LTSL: Targeted delivery using heat-sensitive liposomes

Read More

Immunotherapy

TheraPlas: A novel approach to improve safety and efficacy of gene-based therapies

Read More

RNAi

TheraSilence™ Using systemic RNAi delivery to fight and prevent tumor growth

Read More

Our lead product candidates

Our lead product candidate is ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently being evaluated in a phase 3 clinical trial for the treatment of primary liver cancer (OPTIMA Study) and a phase 2 clinical trial for the treatment of recurrent chest wall breast cancer (EU-DIGNITY Study). Second in our pipeline is GEN-1, a DNA-mediated immunotherapy for the localized treatment of ovarian and brain cancers.

Celsion is headquartered in Lawrenceville, New Jersey. Our discovery and preclinical operations, as well as our analytical services and laboratory functions, are based in Huntsville, Alabama.

ThermoDox is a registered trademark of Celsion Corporation.
TheraPlas and TheraSilence are trademarks of Celsion Corporation.

Share This